Top-Analysts PicksInvest alongside the top 15% of Wall Street analysts.

Try Top-Picks
Myriad Genetics, Inc. Banner

Myriad Genetics, Inc.

MYGN Stock Analysis

Page title

Section title

About Myriad Genetics, Inc.

Medical - Diagnostics & Research
Healthcare

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications...

Myriad Genetics, Inc. Key Metrics

Market Cap
$3B
52 Weeks Low
$13.82
52 Weeks High
$29.30
P/B
3.40x
P/E
-10.02x
P/S
4.64x

Upcoming Events

    MYGN Analyst Forecasts

    ‌
    ‌

    MYGN Financials

    MYGN Income Statement Key Metrics

    • Revenue(TTM)734.40 M
    • Gross Profit(TTM)505.90 M
    • EBITDA(TTM)-212.40 M
    • Net Income(TTM)-274.40 M
    • EPS Diluted(TTM)-3.36

    Decode MYGN's Latest Earnings Call with Ease

    Tap 'Generate' for a crystal-clear,
    AI-crafted summary and stay ahead in the investment game!

    MYGN earnings and revenue history

    MYGN Return on Equity

    See how efficiently MYGN generates profit for it's shareholders.

    0%

    10
    0
    100

    1. Poor

    2. Average

    3. Strong

    Return on Equity Growth

    MYGN's Return on Equity has shown poor growth over the past 10 years, increasing by only 6.40%.

    MYGN Revenue Growth

    See how MYGN has grown it's revenue over the past 10 years.

    ‌

    Revenue Growth

    MYGN's revenue has shown poor growth over the past 10 years, increasing by only -1.36%.